无锡药明康德新药开发股份有限公司关于出售部分股票资产的公告

Group 1 - The company has authorized its investment department to dispose of its publicly traded shares, with a total transaction amount not exceeding 15% of the latest audited net assets attributable to the parent company [2] - The company sold 50,800,000 shares of WuXi XDC Cayman Inc., representing approximately 4.23% of its total share capital, for about HKD 2.178 billion, which accounts for 3.43% of the company's latest audited net assets [3] - The cash proceeds from the sale will be used to accelerate global capacity and capability building, attract and retain talent, and strengthen the company's integrated CRDMO business model [4] Group 2 - The estimated investment income from the sale of WuXi XDC shares is approximately RMB 1.847 billion, which exceeds 10% of the company's latest audited net profit attributable to the parent company [4] - The impact on the company's net profit for the first half of 2025 is estimated to be around RMB 1.847 billion [4]